Disturbed Matrix Metalloproteinase Pathway in Both Age-Related Macular Degeneration and Alzheimer’s Disease

Table 1

Details of control and AD donors utilized in the study.

Donor; number	Status	Age; (years)	Sex	Histological diagnosis	Postmortemdelay (hours)	Braak stage
1	Control	74	F	No significant abnormalities	39.5	1
2	Control	86	F	No AD, moderate CAA	32	2
3	Control	85	M	No significant abnormalities	30.5	2
4	Control	79	F	No significant neuropathological abnormality	48	2
5	AD	78	M	AD moderate to severe	49.5	6
6	AD	81	M	AD probable	11	5
7	AD	85	F	AD definite, moderate atherosclerotic small vessel disease, moderate to marked CAA	14	5
8	AD	73	F	AD definite, moderate CAA	50.5	5
9	AD	78	F	AD definite	61	6

AD, Alzheimer’s disease; CAA, cerebral amyloid angiopathy.